CORRESP Filing
Altimmune, Inc.
Date: Dec. 3, 2025 · CIK: 0001326190 · Accession: 0001104659-25-118172
AI Filing Summary & Sentiment
Reasoning
Letter
Altimmune, Inc.
910 Clopper Road, Suite 201S
Gaithersburg, Maryland 20878
December 3, 2025
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: Altimmune, Inc.: Registration Statement on Form S-3/A, filed November 13, 2025 (File No. 333- 291329)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Act "), Altimmune, Inc. (the " Company ") hereby requests that the effective date of the above-referenced registration statement (the " Registration Statement ") be accelerated to December 5, 2025, at 5:00 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP (" Goodwin "), request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin, by calling Justin Anslow at (212) 459-7126. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin, Attention: Justin Anslow, by email at JAnslow@goodwinlaw.com.
If you have any questions regarding this request, please contact Justin Anslow of Goodwin at (212) 459-7126.
Sincerely,
Altimmune, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Altimmune, Inc.
910 Clopper Road, Suite 201S
Gaithersburg, Maryland 20878
December 3, 2025
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re:
Altimmune, Inc.: Registration Statement on Form S-3/A, filed November 13, 2025 (File No. 333- 291329)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the
" Act "), Altimmune, Inc. (the " Company ") hereby requests that the effective date of the above-referenced
registration statement (the " Registration Statement ") be accelerated to December 5, 2025, at 5:00 pm Eastern Time,
or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP (" Goodwin "), request by
telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company
acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm
the event with our counsel, Goodwin, by calling Justin Anslow at (212) 459-7126. We also respectfully request that a copy of the written
order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel,
Goodwin, Attention: Justin Anslow, by email at JAnslow@goodwinlaw.com.
If you have any questions regarding this request, please contact Justin
Anslow of Goodwin at (212) 459-7126.
Sincerely,
Altimmune, Inc.
/s/ Gregory Weaver
Gregory Weaver
Chief Financial Officer
cc:
Vipin K. Garg, Altimmune, Inc.
Joseph Theis, Esq., Goodwin Procter LLP
Justin Anslow, Esq., Goodwin Procter LLP